Investigation and need of Bioequivalence Study: Methodology and Regulatory Requirement

ISSN: 2213-4778 (Online)
ISSN: 2213-476X (Print)


Volume 1, 3 Issues, 2014


Download PDF Flyer




Applied Clinical Research, Clinical Trials and Regulatory Affairs

Aims & ScopeAbstracted/Indexed in


Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Satish Chandra
Tawam Hospital
Al Ain
UAE


View Full Editorial Board

Subscribe Order Reprints


Investigation and need of Bioequivalence Study: Methodology and Regulatory Requirement

Author(s): Uzma Farooq, Rishabha Malviya and Pramod Kumar Sharma

Affiliation: Research Scholar, Department of Pharmacy, School of Medical and Allied Sciences, Galgotias University, Plot No. 2, Sector 17-A, Yamuna Expressway, Greater Noida, Gautam Buddha Nagar, Uttar Pradesh, India.

Abstract

Bioavailability and bioequivalence studies play a major function in the drug development phase for both new formulations and their generic equivalents. There are various investigations to assess bioequivalence and each regulatory authority has its own guidance for the conduction of bioavailability and bioequivalence studies before approval of generic products. Bioequivalence studies are the primary needs for generic products to enter in the market. The manufacturer (generic) must be in limit with that of innovator (branded) formulation (reference listed drug). This review deals with methods of bioavailability studies and requirement of bioequivalence studies necessary for filing of data for the approval of formulation.

Keywords: Bioavailability, bioequivalence, regulatory requirement, generic drug, pharmacokinetic, therapeutic equivalence, in-vitro and in-vivo

Purchase Online Order Reprints Order Eprints Rights and Permissions

  
  



Article Details

Volume: 1
First Page: 1
Last Page: 14
Page Count: 14
DOI: 10.2174/2213476X01666140613221900
Advertisement


Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science